secondary prevention


Summary: The prevention of recurrences or exacerbations of a disease or complications of its therapy.

Top Publications

  1. Spinelli M. Postpartum psychosis: detection of risk and management. Am J Psychiatry. 2009;166:405-8 pubmed publisher
  2. McCabe M, Bhatia S, Oeffinger K, Reaman G, Tyne C, Wollins D, et al. American Society of Clinical Oncology statement: achieving high-quality cancer survivorship care. J Clin Oncol. 2013;31:631-40 pubmed publisher
  3. Perrin S, Smith P, Yule W. The assessment and treatment of Post-traumatic Stress Disorder in children and adolescents. J Child Psychol Psychiatry. 2000;41:277-89 pubmed
    ..This article presents an overview of the literature on the clinical characteristics, assessment, and treatment of PTSD in children and adolescents. ..
  4. Henrich T, Hatano H, Bacon O, Hogan L, Rutishauser R, Hill A, et al. HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study. PLoS Med. 2017;14:e1002417 pubmed publisher
    ..Extensive testing of blood and tissue for HIV persistence was performed, and PrEP Participant A underwent analytical treatment interruption (ATI) following 32 weeks of continuous ART...
  5. Ariotti S, van Leeuwen M, Brugaletta S, Leonardi S, Akkerhuis K, Rexhaj E, et al. Rationale and design of the Hunting for the off-target propertIes of Ticagrelor on Endothelial function and other Circulating biomarkers in Humans (HI-TECH) trial. Am Heart J. 2017;189:128-136 pubmed publisher
  6. Zhang Y, Chen S, Xiao Y, Tang W. Effects of Dexamethasone in the Treatment of Recurrent Chronic Subdural Hematoma. World Neurosurg. 2017;105:115-121 pubmed publisher
    ..Patients with recurrent CSDH can be treated successfully and safely with the nonsurgical medical treatment of dexamethasone. By use of this method, reoperation may be avoided. ..
  7. Elliott J, Wang T, Gamble G, Williams M, Matsis P, Troughton R, et al. A decade of improvement in the management of New Zealand ST-elevation myocardial infarction (STEMI) patients: results from the New Zealand Acute Coronary Syndrome (ACS) Audit Group national audits of 2002, 2007 and 2012. N Z Med J. 2017;130:17-28 pubmed
    ..001. The use of proven secondary prevention medications at discharge also increased during the decade...
  8. Friedmann P. Clinical practice. Alcohol use in adults. N Engl J Med. 2013;368:365-73 pubmed publisher
  9. Fey M, Dreyling M. Acute myeloblastic leukaemias and myelodysplastic syndromes in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21 Suppl 5:v158-61 pubmed publisher

More Information


  1. Bederson J, Connolly E, Batjer H, Dacey R, Dion J, Diringer M, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke. 2009;40:994-1025 pubmed publisher
  2. Nissen S. Cardiovascular outcomes in randomized trials: should time to first event for "hard" end points remain the standard approach?. J Am Coll Cardiol. 2009;54:2363-5 pubmed publisher
  3. Larkin G, Beautrais A. Emergency departments are underutilized sites for suicide prevention. Crisis. 2010;31:1-6 pubmed publisher
  4. Kreijkamp Kaspers S, Hawke K, Guo L, Kerin G, Bell Syer S, Magin P, et al. Oral antifungal medication for toenail onychomycosis. Cochrane Database Syst Rev. 2017;7:CD010031 pubmed publisher
    ..The main reasons to downgrade evidence were limitations in study design, such as unclear allocation concealment and randomisation as well as lack of blinding. ..
  5. Pilling S, Anderson I, Goldberg D, Meader N, Taylor C. Depression in adults, including those with a chronic physical health problem: summary of NICE guidance. BMJ. 2009;339:b4108 pubmed publisher
  6. Modi S, Callahan T, Rodrigues J, Kajoka M, Dale H, Langa J, et al. Overcoming Health System Challenges for Women and Children Living With HIV Through the Global Plan. J Acquir Immune Defic Syndr. 2017;75 Suppl 1:S76-S85 pubmed publisher
    ..Although progress has been rapid, health systems still face important challenges, particularly follow-up and diagnosis of HIV-exposed infants, continuity of care, and the promotion of services that are respectful and client centered. ..
  7. Gwinnutt J, Symmons D, MacGregor A, Chipping J, Lapraik C, Marshall T, et al. Predictors of and outcomes following orthopaedic joint surgery in patients with early rheumatoid arthritis followed for 20 years. Rheumatology (Oxford). 2017;56:1510-1517 pubmed publisher
    ..17 (95% CI 0.03, 0.32)]. HAQ was the strongest predictor of future major surgery. This supports the argument that HAQ should be included in routine clinical assessment. ..
  8. Raparelli V, Pannitteri G, Todisco T, Toriello F, Napoleone L, Manfredini R, et al. Treatment and Response to Statins: Gender-related Differences. Curr Med Chem. 2017;24:2628-2638 pubmed publisher
    ..The present review summarizes the sex and gender differences in the use of statins, pointing out new perspectives and opening issues in sex-tailored CVD prevention strategy. ..
  9. Manktelow B, Potter J. Interventions in the management of serum lipids for preventing stroke recurrence. Cochrane Database Syst Rev. 2009;:CD002091 pubmed publisher
    ..In view of this and the evidence of the benefit of statin therapy in those with a history of CHD, patients with ischaemic stroke or TIA, with or without a history of established CHD, should receive statins. ..
  10. Kevin Baird J. Malaria caused by Plasmodium vivax: recurrent, difficult to treat, disabling, and threatening to life--the infectious bite preempts these hazards. Pathog Glob Health. 2013;107:475-9 pubmed publisher
    ..This commentary emphasizes the dire consequences of infection by P. vivax and the real difficulty of dealing with them. That, in turn, emphasizes the many benefits to be derived by preventing them in the first place. ..
  11. Armstrong D, Boulton A, Bus S. Diabetic Foot Ulcers and Their Recurrence. N Engl J Med. 2017;376:2367-2375 pubmed publisher
  12. Rothmund F, Gerss J, Ruperto N, Däbritz J, Wittkowski H, Frosch M, et al. Validation of relapse risk biomarkers for routine use in patients with juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2014;66:949-55 pubmed
    ..The tested commercial MRP-8/MRP-14 and S100A12 ELISAs showed a performance comparable to well-established experimental ELISA protocols when assay-specific cutoffs for the indication of relapse prediction are thoroughly applied. ..
  13. Athanasou N, Bielack S, de Alava E, Dei Tos A, Ferrari S, Gelderblom H, et al. Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21 Suppl 5:v204-13 pubmed publisher
  14. Harmon K, Drezner J, Gammons M, Guskiewicz K, Halstead M, Herring S, et al. American Medical Society for Sports Medicine position statement: concussion in sport. Clin J Sport Med. 2013;23:1-18 pubmed publisher
  15. Konieczny G, Morasiewicz P, Kuciel N. The effects of an early intrahospital rehabilitation on weight bearing during lower extremity lengthening with Ilizarov method. Acta Bioeng Biomech. 2017;19:59-64 pubmed
    ..In spite of strict physiotherapy regimen, patients are neither able to equally distribute their body weight between the two lower limbs nor to shift their body weight to the limb equipped with Ilizarov apparatus. ..
  16. Rabar S, Harker M, O Flynn N, Wierzbicki A. Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance. BMJ. 2014;349:g4356 pubmed publisher
  17. Clark W, Strickland S, Barrett A, Savani B. Extramedullary relapses after allogeneic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome. Haematologica. 2010;95:860-3 pubmed publisher
  18. Mas J, Derumeaux G, Guillon B, Massardier E, Hosseini H, Mechtouff L, et al. Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke. N Engl J Med. 2017;377:1011-1021 pubmed publisher
    ..PFO closure was associated with an increased risk of atrial fibrillation. (Funded by the French Ministry of Health; CLOSE number, NCT00562289 .). ..
  19. Grützmacher P, Ohm B, Szymczak S, Dorbath C, Brzoska M, Kleinert C. Primary and secondary prevention of cardiovascular disease in patients with hyperlipoproteinemia (a). Clin Res Cardiol Suppl. 2017;12:22-26 pubmed publisher
    ..Lp(a) apheresis is an established treatment in Germany for secondary prevention of progressive cardiovascular disease...
  20. DeBate R, Bleck J, Raven J, Severson H. Using Intervention Mapping to Develop an Oral Health e-Curriculum for Secondary Prevention of Eating Disorders. J Dent Educ. 2017;81:716-725 pubmed publisher
    ..evidence-based intervention with the goal of increasing the capacity of oral health providers to engage in secondary prevention of oral-systemic issues associated with disordered eating behaviors...
  21. Leigh I. Progress in skin cancer: the U.K. experience. Br J Dermatol. 2014;171:443-5 pubmed publisher
  22. Hollon S. Cognitive and behavior therapy in the treatment and prevention of depression. Depress Anxiety. 2011;28:263-6 pubmed publisher
  23. Cohen J. Breakthrough of the year. HIV treatment as prevention. Science. 2011;334:1628 pubmed publisher
  24. Rosansky S. The sad truth about early initiation of dialysis in elderly patients. JAMA. 2012;307:1919-20 pubmed publisher
  25. Lindholm D, Lindback J, Armstrong P, Budaj A, Cannon C, Granger C, et al. Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary Disease. J Am Coll Cardiol. 2017;70:813-826 pubmed publisher
    ..The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial [STABILITY]; NCT00799903). ..
  26. Tieu J, Shepherd E, Middleton P, Crowther C. Interconception care for women with a history of gestational diabetes for improving maternal and infant outcomes. Cochrane Database Syst Rev. 2017;8:CD010211 pubmed publisher
  27. Sehra D, Sehra S, Sehra S. Cardiovascular pleiotropic effects of statins and new onset diabetes: is there a common link: do we need to evaluate the role of KATP channels?. Expert Opin Drug Saf. 2017;16:823-831 pubmed publisher
    ..This disturbs the carbohydrate metabolism and probably leads to diabetes. In our opinion, use of stains should be more judicious and restricted to secondary prevention only.
  28. McNew B, Darbro B, Ma D, Gordon D. Development of Secondary Acute Myeloid Leukemia in a Pediatric Patient Concurrently Receiving Primary Therapy for Ewing Sarcoma. J Pediatr Hematol Oncol. 2017;39:e370-e372 pubmed publisher
    ..This report highlights the importance of monitoring for treatment-related effects in cancer therapy, as well as the need for novel, less toxic approaches in Ewing sarcoma therapy. ..
  29. Huber D, Henriksson R, Jakobsson S, Mooe T. Nurse-led telephone-based follow-up of secondary prevention after acute coronary syndrome: One-year results from the randomized controlled NAILED-ACS trial. PLoS ONE. 2017;12:e0183963 pubmed publisher
    b>Secondary prevention after acute coronary syndrome (ACS) could reduce morbidity and mortality, but guideline targets are seldom reached. We hypothesized that nurse-led telephone-based intervention would increase adherence...
  30. Peersen K, Munkhaugen J, Gullestad L, Dammen T, Moum T, Otterstad J. Reproducibility of an extensive self-report questionnaire used in secondary coronary prevention. Scand J Public Health. 2017;45:269-276 pubmed publisher
    ..It thus emerges as a valuable tool for evaluating patient factors associated with coronary risk factor control in CHD patients. ..
  31. Bhatt G, Das R. Early versus late initiation of renal replacement therapy in patients with acute kidney injury-a systematic review & meta-analysis of randomized controlled trials. BMC Nephrol. 2017;18:78 pubmed publisher
    ..This updated meta-analysis showed no added benefit of early initiation of RRT for patients with AKI. The grade evidence generated was of "low quality" and there was a high heterogeneity in the included trials. CRD42016043092 . ..
  32. Guzik A, Bushnell C. Stroke Epidemiology and Risk Factor Management. Continuum (Minneap Minn). 2017;23:15-39 pubmed publisher
    ..This article incorporates evidence from guidelines and published studies and uses an illustrative case study throughout the article to provide examples of secondary prevention management of stroke risk factors.
  33. Bockeria O, Akhobekov A, Shvartz V, Kudzoeva Z. [Efficacy of Statin Therapy in the Prevention of Atrial Fibrillation in Early Postoperative Period after Coronary Artery Bypass Grafting]. Vestn Ross Akad Med Nauk. 2015;:273-8 pubmed
    ..099 for "number of grafts". Odds ratio was 0.2 (95% CI 0.08-0.5). Statin therapy prior to and after GABG wasfound to be an effective method of primary prevention of AF in the early postoperative period. ..
  34. Bechdolf A, Klingberg S. [Psychotherapy of schizophrenia: not a problem of evidence, but a problem of implementation]. Psychiatr Prax. 2014;41:8-10 pubmed publisher
  35. Neumann U, Biermer M, Eurich D, Neuhaus P, Berg T. Successful prevention of hepatitis C virus (HCV) liver graft reinfection by silibinin mono-therapy. J Hepatol. 2010;52:951-2 pubmed publisher
  36. Colombo N, Peiretti M, Parma G, Lapresa M, Mancari R, Carinelli S, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21 Suppl 5:v23-30 pubmed publisher
  37. Zhao M, Klipstein Grobusch K, Wang X, Reitsma J, Zhao D, Grobbee D, et al. Prevalence of cardiovascular medication on secondary prevention after myocardial infarction in China between 1995-2015: A systematic review and meta-analysis. PLoS ONE. 2017;12:e0175947 pubmed publisher
    ..With a rapidly increasing number of MI patients in China, a comprehensive strategy on secondary prevention is warranted. PROSPERO (CRD42015025246).
  38. Bowen S, Somohano V, Rutkie R, Manuel J, Rehder K. Mindfulness-Based Relapse Prevention for Methadone Maintenance: A Feasibility Trial. J Altern Complement Med. 2017;23:541-544 pubmed publisher
    ..Results from this initial pilot trial support feasibility and acceptability, and provide preliminary data on outcomes for future trials of mindfulness-based approaches within the MMT community. ..
  39. . Prevention of hepatocellular carcinoma in the Asia-Pacific region: consensus statements. J Gastroenterol Hepatol. 2010;25:657-63 pubmed publisher
    ..Widespread application of HCC surveillance in Asia-Pacific countries depends on economic factors and health-care priorities. ..
  40. Giacomet V, Trabattoni D, Zanchetta N, Biasin M, Gismondo M, Clerici M, et al. No cure of HIV infection in a child despite early treatment and apparent viral clearance. Lancet. 2014;384:1320 pubmed publisher
  41. Sánchez Ballester F, Ruiz Vidal V, López Alcina E, Domenech Perez C, Escudero Fontano E, Oltra Benavent A, et al. Cysticlean® a highly pac standardized content in the prevention of recurrent urinary tract infections: an observational, prospective cohort study. BMC Urol. 2013;13:28 pubmed publisher
    ..Prophylaxis with American cranberry extract (Cysticlean®) could be an alternative to classical therapies with antibiotics. Further studies are needed to confirm results obtained in this pilot study. ..
  42. Ivers N, Schwalm J, Witteman H, Presseau J, Taljaard M, McCready T, et al. Interventions Supporting Long-term Adherence aNd Decreasing cardiovascular events (ISLAND): Pragmatic randomized trial protocol. Am Heart J. 2017;190:64-75 pubmed publisher
    ..of cardiac medications for most patients who have had a myocardial infarction (MI), but adherence to these secondary prevention treatments is suboptimal. This is a multicenter, pragmatic, 3-arm randomized trial...
  43. Capewell S, Lloyd Jones D. Optimal cardiovascular prevention strategies for the 21st century. JAMA. 2010;304:2057-8 pubmed publisher
  44. Hooton T. Clinical practice. Uncomplicated urinary tract infection. N Engl J Med. 2012;366:1028-37 pubmed publisher
  45. Torp Pedersen C, Møller M, Bloch Thomsen P, Køber L, Sandøe E, Egstrup K, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med. 1999;341:857-65 pubmed
    ..Dofetilide had no effect on mortality. ..
  46. Crino L, Weder W, Van Meerbeeck J, Felip E. Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21 Suppl 5:v103-15 pubmed publisher
  47. Kagolanu D, Sayedy N, Haseeb S, Shah S, Lam P, Munnangi S, et al. Usefulness of PA32540 in Protecting the Gastric Layer While Providing Secondary Prevention for Coronary Artery Disease. Am J Cardiol. 2017;120:1118-1121 pubmed publisher
    Aspirin has been the mainstay for secondary prevention of coronary artery disease to decrease early recurrence and severity of recurrent cardiovascular events...
  48. de Campos T, Maher C, Clare H, da Silva T, Hancock M. Effectiveness of McKenzie Method-Based Self-Management Approach for the Secondary Prevention of a Recurrence of Low Back Pain (SAFE Trial): Protocol for a Pragmatic Randomized Controlled Trial. Phys Ther. 2017;97:799-806 pubmed publisher
    ..of this study was to determine the effectiveness of a McKenzie method-based self-management approach in the secondary prevention of LBP. This will be a pragmatic randomized controlled trial...
  49. West S, Moncada J, Munoz B, Mkocha H, Storey P, Hardick J, et al. Is there evidence for resistance of ocular Chlamydia trachomatis to azithromycin after mass treatment for trachoma control?. J Infect Dis. 2014;210:65-71 pubmed
    ..50 µg/mL. There is no evidence that continued infection after MDA was due either to resistance to azithromycin or to a heavier load of organism before treatment. Other potential causes of persistent infection need to be evaluated. ..
  50. Layden J, Michaels J, Bermingham S, Higgins B. Diagnosis and management of lower limb peripheral arterial disease: summary of NICE guidance. BMJ. 2012;345:e4947 pubmed publisher
  51. Ridker P, Everett B, Thuren T, MacFadyen J, Chang W, Ballantyne C, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017;377:1119-1131 pubmed publisher
    ..Funded by Novartis; CANTOS number, NCT01327846 .). ..
  52. Swift R. Naltrexone and nalmefene: any meaningful difference?. Biol Psychiatry. 2013;73:700-1 pubmed publisher
  53. Schmidt A, Pearce L, Wilkins J, Overington J, Hingorani A, Casas J. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2017;4:CD011748 pubmed publisher
    ..Finally, estimated risk differences indicate that PCSK9 inhibitors only modestly change absolute risks (often to less than 1%). ..